Supplementary Figure S1 from Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (225Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate Cancer
Key Points
Key points are not available for this paper at this time.
Abstract
Figure S1. 225Ac-pelgi induces the phosphorylation of DNA damage markers in LNCaP, C4-2, and 22Rv1 prostate cancer cells
Supplementary Figure S1 from Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (225Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate Cancer | Synapse